Abstract
TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Protein & Peptide Letters
Title: Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris
Volume: 19 Issue: 3
Author(s): Rui Wang, Shiliang Zhou, Xiaomin Peng, Xin-Wen Zhou, Zhi-Qun Xie, Yuxiong Wang, Wei Mo and Min Yu
Affiliation:
Keywords: TACI, CRD2, BAFF, APRIL, affinity, autoimmune disorders, Novagen, DNA ligase, homology modeling, Pichia pastoris
Abstract: TACI is a member of the tumor necrosis factor receptor superfamily and serves as a key regulator of B cell function. The extracellular domain of a typical TNFR contains multiple copies of CRD, which bind in the monomermonomer interfaces of a trimeric ligand. TACI binds to two ligands, APRIL and BAFF, with high affinity and contains two CRD in its extracellular regions, while BCMA and BR3, contain a single or partial CRD for binding the two ligands. However, TACI can be classified as a single CRD receptor because the amino-terminal CRD1 doesnt contribute to ligand binding. To obtain a new variant of TACI possessing higher affinities for binding, we fused a repeat sequence of CRD2 to the N-terminus of the short form of TACI. The new APRIL antagonist peptide, CRD2-shortTACI-Fc, was designed based on the modeling 3-D complex structure of TACI and APRIL. As expected, the purified recombinant CRD2-shortTACI-Fc fusion protein could bind to APRIL in vitro and demonstrated dose-dependent inhibition of APRIL-induced proliferative activity in Raji cells. We found that CRD2-shortTACI-Fc, has a higher affinity for binding to ligands than short-TACI-Fc, which contains a single CRD2.
Export Options
About this article
Cite this article as:
Wang Rui, Zhou Shiliang, Peng Xiaomin, Zhou Xin-Wen, Xie Zhi-Qun, Wang Yuxiong, Mo Wei and Yu Min, Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris, Protein & Peptide Letters 2012; 19 (3) . https://dx.doi.org/10.2174/092986612799363136
DOI https://dx.doi.org/10.2174/092986612799363136 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Patents Targeting Interleukin-17A; Implications in Cancer and Inflammation
Recent Patents on Anti-Cancer Drug Discovery Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Diagnostic and Prognostic Potential of the Macrophage Specific Receptor CD163 in Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Protective Effects of Chronic Green Tea Consumption on Age-related Neurodegeneration
Current Pharmaceutical Design Peptides Against Autoimmune Neurodegeneration
Current Medicinal Chemistry Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Concurrent Use of Antiretrovirals and Anticonvulsants in Human Immunodeficiency Virus (HIV) Seropositive Patients
Current Pharmaceutical Design Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Nitric Oxide-GAPDH Transcriptional Signaling Mediates Behavioral Actions of Cocaine
CNS & Neurological Disorders - Drug Targets CD4+ T-cell Count may not be a Useful Strategy to Monitor Antiretroviral Therapy Response in HTLV-1/HIV Co-infected Patients
Current HIV Research Identification of Small Molecule Binding Sites within Proteins Using Phage Display Technology
Combinatorial Chemistry & High Throughput Screening HIV-1 Tat-Mediated Calcium Dysregulation and Neuronal Dysfunction in Vulnerable Brain Regions
Current Drug Targets Structure-Function Relationships and Clinical Applications of L-Asparaginases
Current Medicinal Chemistry dUTPase in Human Neoplastic Cells as a Potential Target for Therapeutic Intervention
Current Protein & Peptide Science Platelet Protein Synthesis and Translational Control
Current Proteomics Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Current Gene Therapy Hyaluronic Acid as a Protein Polymeric Carrier: An Overview and a Report on Human Growth Hormone
Current Drug Targets Genetic Mechanisms and Aberrant Gene Expression during the Development of Gastric Intestinal Metaplasia and Adenocarcinoma
Current Genomics